Announcement on updated scoping study should be just about due. Previous guidance suggested sometime in October. Further drilling also scheduled to commence in October.
Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market
TLX Telix gets its foot in the FDA door bringing prostate cancer detection closer to neglected Americans